English (UK)
中文版BirdoTech 
Shanghai based CRO and CDMO with offices in the US and Germany.
Branden Lee
Dir. Business DevelopmentBridge Point Capital 
We are a cross-border private equity fund dedicated to actively pursuing primarily late stage U.S healthcare companies that will benefit from penetrating the vast Asian healthcare market. We identify the well-managed western companies with advanced technology or systems to disrupt the global healthcare market, especially the ones with great market potential in Asia.
Miss Nadia Tian
Founding PartnerBRIMED PHARMA GROUP
Founded in Wuxi, 2017
Focus on development, manufacturing and marketing of drugs
Registered capital is RMB 280M
Consists of Wuxi Fortune, Qingzhipin Pharma and Sihuan Pharma
Annual revenues - RMB 1 billion (~0.5 billion for antibiotics)
To be public company within 5 years in China
Focus on development, manufacturing and marketing of drugs
Registered capital is RMB 280M
Consists of Wuxi Fortune, Qingzhipin Pharma and Sihuan Pharma
Annual revenues - RMB 1 billion (~0.5 billion for antibiotics)
To be public company within 5 years in China
Responsive Web Design powered by 